PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
AE36 HER2/neu-derived Peptide Linked to Positively Charged Liposomes with CpG-ODN as an Effective Therapeutic and Prophylactic Vaccine for Breast Cancer
Barati, N.; Nikpoor, A. R.; Mosaffa, F.; Razazan, A.; Badiee, A.; Motavallihaghi, S. M.; Behravan, J.; Jaafari, M. R. AE36 HER2/Neu-Derived Peptide Linked to Positively Charged Liposomes with CpG-ODN as an Effective Therapeutic and Prophylactic Vaccine for Breast Cancer. Journal of Drug Delivery Science and Technology, 2022, 67, 102904. https://doi.org/10.1016/j.jddst.2021.102904.
Barati, N.; Nikpoor, A. R.; Mosaffa, F.; Razazan, A.; Badiee, A.; Motavallihaghi, S. M.; Behravan, J.; Jaafari, M. R. AE36 HER2/Neu-Derived Peptide Linked to Positively Charged Liposomes with CpG-ODN as an Effective Therapeutic and Prophylactic Vaccine for Breast Cancer. Journal of Drug Delivery Science and Technology, 2022, 67, 102904. https://doi.org/10.1016/j.jddst.2021.102904.
Barati, N.; Nikpoor, A. R.; Mosaffa, F.; Razazan, A.; Badiee, A.; Motavallihaghi, S. M.; Behravan, J.; Jaafari, M. R. AE36 HER2/Neu-Derived Peptide Linked to Positively Charged Liposomes with CpG-ODN as an Effective Therapeutic and Prophylactic Vaccine for Breast Cancer. Journal of Drug Delivery Science and Technology, 2022, 67, 102904. https://doi.org/10.1016/j.jddst.2021.102904.
Barati, N.; Nikpoor, A. R.; Mosaffa, F.; Razazan, A.; Badiee, A.; Motavallihaghi, S. M.; Behravan, J.; Jaafari, M. R. AE36 HER2/Neu-Derived Peptide Linked to Positively Charged Liposomes with CpG-ODN as an Effective Therapeutic and Prophylactic Vaccine for Breast Cancer. Journal of Drug Delivery Science and Technology, 2022, 67, 102904. https://doi.org/10.1016/j.jddst.2021.102904.
Abstract
In the present day and age, cancer is still a life-limiting factor whose one of the therapeutic strategies is immunotherapy with vaccines. This research aims to prepare and characterize nanoliposomal vaccine formulation attached to HER2/neu-derived peptide (AE36) with or without CpG-ODN, and to evaluate its immunological responses to the therapy using BALB/c mice with HER2 overexpressing breast cancer. Methods: AE36 was conjugated to the liposomes containing DOTAP, DOPE and Cholesterol. Such formulations are able to produce CD8+ and CD4+ responses and induce synthesis of cytokines detectable via Enzyme-linked immunosorbent assay kits, cytotoxicity testing and intracellular cytokine staining combined with flow cytometry. Therapeutic and prophylactic effectiveness were evaluated through the formulation in samples. The highest effectiveness was found in DDC-peptide + CpG-ODN in both prophylactic and therapeutic studies, which decreased the size of tumors significantly and increased time of survival. These nanoliposomes linked to AE36 could be regarded as an appropriate candidate for the treatment and also for prophylaxis of HER2+ breast cancer; however further studies are needed.
Keywords
AE36 HER2/neu-derived peptide; Nanoliposomes; CpG-ODN; Vaccine; Cancer
Subject
Biology and Life Sciences, Anatomy and Physiology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
